Alexander Y. Rudensky, Ph.D., Genentech CLIP InvestigatorMemorial Sloan Kettering Cancer Center

The basic research our lab and others are doing to determine how regulatory T cells are formed and how they function is likely to have widespread clinical applications.
Area of Research: All Cancers

While regulatory T cells (Tregs) are important for preventing autoimmune responses against healthy tissues, they can also suppress immune responses against cancer cells and, as a result, allow tumors to thrive. To address the potentially pro-cancer activity of Tregs, Dr. Alexander Rudensky is evaluating a Treg-depleting drug called KW-0761, and through an early phase clinical trial his team seeks to determine the appropriate dose and potential effectiveness of KW-0761. Ideally, these studies will lead to a better understanding of the role Tregs play in promoting cancer progression and help assess how well this Treg-depletion strategy works as a novel cancer immunotherapy.

Projects and Grants

Immunoregulatory correlates of a phase I/II study of mogamulizumab (KW-0761) in subjects with advanced and/or metastatic solid tumors

Memorial Sloan Kettering Cancer Center | All Cancers | 2014

Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.